| Symbol | LIXT |
|---|---|
| Name | LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 433 PLAZA REAL,SUITE 275, BOCA RATON, Florida, 33432, United States |
| Telephone | +1 631 830-7092 |
| Fax | — |
| — | |
| Website | https://www.lixte.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001335105 |
| Description | Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors. Additional info from NASDAQ: |
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
Read moreDirector Pursglove Geordan Garrett 🟡 adjusted position in 0 shares (1 derivative) of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) at $2.83 Transaction Date: Apr 15, 2026 | Filing ID: 017855
Read moreStazzone Peter 🟡 adjusted position in 0 shares (1 derivative) of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) at $4.45 Transaction Date: Apr 15, 2026 | Filing ID: 017857
Read moreDirector Sawyer Jason David 🟡 adjusted position in 0 shares (1 derivative) of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) at $3.59 Transaction Date: Apr 15, 2026 | Filing ID: 017856
Read moreDirector Primus Guy Warren 🟡 adjusted position in 0 shares (1 derivative) of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) at $4.05 Transaction Date: Apr 15, 2026 | Filing ID: 017854
Read moreDirector Holloway Michael Andrew 🟡 adjusted position in 0 shares (1 derivative) of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) at $3.59 Transaction Date: Apr 15, 2026 | Filing ID: 017853
Read more(99% Neutral) LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Announces Executive Changes
Read moreFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
Read moreLIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
Read moreNew Form 10-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001493152-26-014052 <b>Size:</b> 11 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03886662 | A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic S… | Phase1 | Myelodysplastic Syndromes | Recruiting | 2019-04-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT01837667 | Phase I Study of LB-100 With Docetaxel in Solid Tumors | Phase1 | Tumors | Completed | 2013-02-01 | 2016-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Docetaxel | Other | Phase PHASE1 | Tumors | COMPLETED | NCT01837667 |
| LB-100 for Injection | Other | Phase PHASE1 | Tumors | COMPLETED | NCT01837667 |
| LB-100 | Other | Phase PHASE1 | Myelodysplastic Syndromes | RECRUITING | NCT03886662 |
| LB-100 | DRUG | Phase PHASE1 | Myelodysplastic Syndromes | RECRUITING | NCT03886662 |
| Docetaxel | DRUG | Phase PHASE1 | Tumors | COMPLETED | NCT01837667 |
| LB-100 for Injection | DRUG | Phase PHASE1 | Tumors | COMPLETED | NCT01837667 |